Israeli study may provide hope for some pancreatic cancer patients

June 4, 2019 by JNS
Read on for article

A groundbreaking study at Israel’s Sheba Medical Center at Tel Hashomer has determined that a targeted cancer therapy drug developed in partnership with pharmaceutical companies AstraZeneca and Merck & Co. Inc. delays the progression of a specific strain of pancreatic cancer, offering “potential hope” for patients suffering from the 12th most common cancer worldwide.

A researcher at the Technion-Israel Institute of Technology in Haifa on Feb. 19, 2019. Photo: Hadas Parush/Flash90.

Talia Golan, head researcher at the Sheba Medical Center Pancreatic Cancer Center, has been testing the safety and efficacy of a new treatment regimen based on olaprib tablets, a medication that attacks a certain enzyme important for the cell development of several forms of cancer.

The study was conducted among 154 patients with metastatic pancreatic cancer who also carried the BRCA1 and BRCA2 genetic mutations, which seriously elevate the risk of breast and ovarian cancers in women.

Research found that those with the mutations lived an average of 7.4 months without pancreatic cancer progression, compared to 3.8 months in the placebo group. The scientists said the results provide “potential hope” for this specific subset of pancreatic cancer patients.

Median survival in the two groups was not drastically different—18.9 months in the test group versus 18.1 months in the placebo group.

Golan presented her findings at the American Society of Clinical Oncology (ASCO) annual conference on Sunday in Chicago, the same day the findings were published in The New England Journal of Medicine.

Pancreatic cancer is the fourth leading cause of cancer death, with a five-year survival rate of 9 per cent.

(JNS)

Speak Your Mind

Comments received without a full name will not be considered
Email addresses are NEVER published! All comments are moderated. J-Wire will publish considered comments by people who provide a real name and email address. Comments that are abusive, rude, defamatory or which contain offensive language will not be published

Got something to say about this?

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Discover more from J-Wire

Subscribe now to keep reading and get access to the full archive.

Continue reading